文献速递性腺与生殖内分泌

血浆雌二醇对早期与晚期绝经后亚临床动脉粥样硬化进展的差异影响

Differential Effect of Plasma Estradiol on Subclinical Atherosclerosis Progression in Early vs Late Postmenopause.
PubMed 文献 · J Clin Endocrinol Metab · 2019-01-01

这项试验后分析基于雌激素早期与晚期干预试验,在596名健康绝经后女性中每6个月检测血浆雌二醇和颈动脉内膜中层厚度(CIMT),平均随访4.8年。结果显示,较高雌二醇水平与早期绝经后CIMT进展减慢相关(P=0.041),与晚期绝经后CIMT进展加快相关(P=0.006),交互作用P<0.001。结论支持激素治疗启动时机假说,早期启动对心血管有益。

要点

  • 早期绝经后较高雌二醇水平与CIMT进展减慢相关。
  • 晚期绝经后较高雌二醇水平与CIMT进展加快相关。
  • 雌二醇与CIMT进展的关联因激素治疗启动时机而异。

核心结论

  • 雌二醇水平与动脉粥样硬化进展的关联因激素治疗启动时机不同而不同。
  • 较高雌二醇水平在早期绝经后使CIMT进展率降低,在晚期绝经后使CIMT进展率增加。
  • 结果支持激素治疗启动时机假说,早期绝经后启动可减少动脉粥样硬化进展。

研究设计与样本

  • 随机对照试验的事后分析,按绝经年限分层(ClinicalTrials.gov no. NCT00114517)。
  • 纳入596名健康绝经后女性,随机接受口服雌二醇联合或不联合周期性阴道孕酮。
  • 每6个月检测血浆雌二醇水平和CIMT,平均随访4.8年。
  • 采用混合效应线性模型检验雌二醇水平与CIMT变化率的关联。

主要发现

  • 在早期绝经后(<6年)女性中,较高雌二醇水平与CIMT进展呈负相关(P=0.041)。
  • 在晚期绝经后(≥10年)女性中,较高雌二醇水平与CIMT进展呈正相关(P=0.006)。
  • 雌二醇水平与绝经时机的交互作用P<0.001。
  • 早期绝经后女性雌二醇水平最低与最高四分位的CIMT进展率分别为8.5和7.2 μm/y。
  • 晚期绝经后女性雌二醇水平最低与最高四分位的CIMT进展率分别为9.8和11.7 μm/y。

临床怎么用

  • 临床启动激素治疗时应考虑绝经年限,早期绝经后启动可能对心血管有益。
  • 对于晚期绝经后女性,较高雌二醇水平可能与动脉粥样硬化进展加快相关,需个体化评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: The Early vs Late Intervention Trial with Estradiol showed that hormone therapy (HT) reduced progression of atherosclerosis when initiated in early but not in late postmenopause. OBJECTIVE: This posttrial analysis examined the association between plasma estradiol (E2) levels and atherosclerosis determined by rate of change in carotid artery intima-media thickness (CIMT) and tested whether this association is equally evident in early (<6 years) vs late (≥10 years) postmenopause. DESIGN: Randomized controlled trial stratified by time since menopause (ClinicalTrials.gov no. NCT00114517). Mixed-effects linear models tested the association of E2 levels with CIMT rate of change. SETTING: Los Angeles, California. PARTICIPANTS: Healthy women in postmenopause. INTERVENTION: Oral E2 with/without cyclic vaginal progesterone. MAIN OUTCOME MEASURES: Plasma E2 levels and CIMT assessed every 6 months over an average of 4.8 years. RESULTS: Among 596 women in postmenopause, higher E2 level was inversely associated with CIMT progression in those in early postmenopause (P = 0.041) and positively associated with CIMT progression in those in late postmenopause (P = 0.006) (P for interaction <0.001). CIMT progression rates for the lowest vs highest quartile of E2 levels among women in early postmenopause were 8.5 and 7.2 μm/y, respectively , whereas among women in late postmenopause they were 9.8 and 11.7 μm/y, respectively. CONCLUSION: E2 levels were differentially associated with atherosclerosis progression according to timing of HT initiation. With higher E2 levels, CIMT progression rate was decreased among women in early postmenopause but increased among women in late postmenopause. These results support the timing hypothesis of HT initiation on cardiovascular benefit, with reduced atherosclerosis progression for initiation during early postmenopause.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Sriprasert I, Hodis HN, Karim R, et al. Differential Effect of Plasma Estradiol on Subclinical Atherosclerosis Progression in Early vs Late Postmenopause. J Clin Endocrinol Metab. 2019. PMID: 30272234. doi:10.1210/jc.2018-01600

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。